Claudia Trenkwalder

Summary

Affiliation: Paracelsus Hospital
Country: Germany

Publications

  1. doi Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations
    Claudia Trenkwalder
    Centre of Parkinsonism and Movement Disorders, Paracelsus Elena Hospital, Kassel, Germany Department of Neurosurgery, University Medical Centre, Goettingen, Germany Electronic address
    Parkinsonism Relat Disord 21:1023-30. 2015
  2. pmc Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features
    Franziska Hopfner
    Institute of Human Genetics, Helmholtz Zentrum Munchen German Research Center for Environmental Health, Neuherberg, Germany
    BMC Neurol 11:134. 2011
  3. doi Restless legs syndrome: pathophysiology, clinical presentation and management
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstrasse 16, 34128 Kassel, Germany
    Nat Rev Neurol 6:337-46. 2010
  4. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
  5. doi Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany Department of Neurosurgery, University of Gottingen, Gottingen, Germany Electronic address
    Lancet Neurol 12:1141-50. 2013
  6. doi α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
  7. doi Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease?
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Kassel, Germany
    Sleep Med 13:1178-83. 2012
  8. pmc Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    J Clin Sleep Med 7:75-80. 2011
  9. doi Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Lancet Neurol 7:595-604. 2008
  10. ncbi Augmentation in restless legs syndrome is associated with low ferritin
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Sleep Med 9:572-4. 2008

Collaborators

Detail Information

Publications41

  1. doi Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations
    Claudia Trenkwalder
    Centre of Parkinsonism and Movement Disorders, Paracelsus Elena Hospital, Kassel, Germany Department of Neurosurgery, University Medical Centre, Goettingen, Germany Electronic address
    Parkinsonism Relat Disord 21:1023-30. 2015
    ..Apomorphine infusion is less invasive than other non-oral treatment options for advancing disease, intrajejunal levodopa infusion and deep-brain stimulation. ..
  2. pmc Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features
    Franziska Hopfner
    Institute of Human Genetics, Helmholtz Zentrum Munchen German Research Center for Environmental Health, Neuherberg, Germany
    BMC Neurol 11:134. 2011
    ..To test the hypothesis whether isolated appearance of individual AMRF syndrome features could be related to heterozygote SCARB2 mutations, we screened for SCARB2 mutations in unrelated patients showing isolated AMRF features...
  3. doi Restless legs syndrome: pathophysiology, clinical presentation and management
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstrasse 16, 34128 Kassel, Germany
    Nat Rev Neurol 6:337-46. 2010
    ..Here, we review the latest studies pertaining to the pathophysiology, clinical presentation and management of RLS...
  4. ncbi Blood-based neurochemical diagnosis of vascular dementia: a pilot study
    Mirko Bibl
    Department of Psychiatry University of Goettingen, von Siebold Str, Goettingen, Germany
    J Neurochem 103:467-74. 2007
    ..From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD...
  5. doi Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany Department of Neurosurgery, University of Gottingen, Gottingen, Germany Electronic address
    Lancet Neurol 12:1141-50. 2013
    ..We investigated the efficacy and safety of a fixed-dose combination of prolonged release oxycodone-naloxone for patients with severe restless legs syndrome inadequately controlled by previous, mainly dopaminergic, treatment...
  6. doi α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
    ..We aimed to assess whether reduction of α-synuclein concentrations in CSF was a marker for α-synuclein deposition in the brain, and therefore diagnostic of synucleinopathies...
  7. doi Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease?
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Kassel, Germany
    Sleep Med 13:1178-83. 2012
    ..To describe the alterations in the macrostructure of sleep in a large cohort of sleep-disturbed patients with Parkinson's disease (PD) and investigate influencing factors...
  8. pmc Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    J Clin Sleep Med 7:75-80. 2011
    ..To develop a polysomnographic video-based scale for rating the severity of REM sleep behavior disorder (RBD), to classify the severity of RBD and to determine the intraindividual variability of RBD in patients with Parkinson disease (PD)...
  9. doi Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Lancet Neurol 7:595-604. 2008
    ..Continuous administration of a dopamine agonist could be used to treat patients with restless legs syndrome. Our aim was to investigate the efficacy of transdermal rotigotine in the treatment of idiopathic restless legs syndrome...
  10. ncbi Augmentation in restless legs syndrome is associated with low ferritin
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Sleep Med 9:572-4. 2008
    ..We aimed to analyze the relationship between baseline ferritin level and occurrence of augmentation in a retrospective analysis of a prospective double-blind trial of cabergoline versus levodopa on augmentation in RLS...
  11. doi Associated factors for REM sleep behavior disorder in Parkinson disease
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Neurology 77:1048-54. 2011
    ..To investigate the frequency, phenomenology, and associated risk factors of REM sleep behavior disorder (RBD) in Parkinson disease (PD)...
  12. doi Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
    Brit Mollenhauer
    From the Center of Parkinsonism and Movement Disorders B M, E T, F S D, T W, J E, M S, E L, C T, Paracelsus Elena Klinik, Kassel Department of Neurosurgery B M, N K F, C T, University Medical Centre, Goettingen Department of Psychology E T, University Kassel Section of Clinical and Molecular Neurogenetics at the Department of Neurology K R K, K L, C K, University of Luebeck Departments of Neuropathology B M and Medical Statistics T F, University Medical Centre, Goettingen, Germany Program in Neuroscience M G S, Ottawa Hospital Research Institute Division of Neurology, The Ottawa Hospital, University of Ottawa, Canada and ReSearch Pharmaceutical Services R K, Nuremberg, Germany
    Neurology 81:1226-34. 2013
    ..To determine nonmotor signs (NMS) and evaluate the utility of several diagnostic tools in patients with de novo Parkinson disease (PD)...
  13. ncbi Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, University of Gottingen, Kassel, Germany
    Mov Disord 22:696-703. 2007
    ..0001). This first large-scale active controlled study in RLS showed superior efficacy of cabergoline versus levodopa after a 30-week long-term therapy. Tolerability was found more favorable with levodopa than with cabergoline...
  14. doi Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Neurosci Lett 532:44-8. 2013
    ..Follow-up investigations will determine the usefulness of CSF α-synuclein values as markers of progression in individual subjects...
  15. ncbi Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG)
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Mov Disord 22:S495-504. 2007
    ..The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols...
  16. doi Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    Mov Disord 23:2267-302. 2008
    ....
  17. doi Parkinson's disease sleep scale--validation of the revised version PDSS-2
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany
    Mov Disord 26:644-52. 2011
    ..The previous Parkinson's disease sleep scale (PDSS) is a 15-item visual analogue scale that assesses the profile of nocturnal disturbances in Parkinson's disease (PD) patients...
  18. doi Rotigotine transdermal delivery for the treatment of restless legs syndrome
    Friederike Sixel-Döring
    Center of Parkinsonism and Movement Disorders, Paracelsus Elena Hospital, Klinikstrasse 16, 34128 Kassel, Germany
    Expert Opin Pharmacother 11:649-56. 2010
    ..Constant drug delivery and ease of use due to the application of an adhesive patch once daily are the potential advantages of the rotigotine patch for the treatment of RLS...
  19. pmc Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen and Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 26:90-9. 2011
    ..Twenty-four-hour transdermal delivery of rotigotine to PD patients with early-morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances...
  20. ncbi Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia
    Brit Mollenhauer
    Department of Neurology, Georg August University, Kassel, Germany
    Dement Geriatr Cogn Disord 22:200-8. 2006
    ..These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD...
  21. doi Recent advances in the diagnosis, genetics and treatment of restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128, Kassel, Germany
    J Neurol 256:539-53. 2009
    ..An overview on therapeutic options and recent trials is given based on evidence-based management strategies for this common disorder...
  22. pmc Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Dtsch Arztebl Int 107:684-91. 2010
    ..Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD). Both of these conditions are often diagnosed late or not at all...
  23. doi Efficacy and safety of dopamine agonists in restless legs syndrome
    Magdolna Hornyak
    Interdisciplinary Pain Centre, University Medical Centre, Breisacher Strasse 64, 79106 Freiburg, Germany
    Sleep Med 13:228-36. 2012
    ..This article is an overview of a comprehensive Cochrane meta-analysis on the efficacy and safety of dopamine agonists (DAs), the first-line treatment of RLS...
  24. doi Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy
    Friederike Sixel-Döring
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Sleep Med 10:407-15. 2009
    ....
  25. doi Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Klinikstrasse 16, 34128 Kassel, Germany
    Biomark Med 4:683-99. 2010
    ..We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts...
  26. doi Restless Legs Syndrome: Psychiatric Comorbidities Are More Important Than Neuroticism
    Ellen Trautmann
    a Paracelsus Elena Klinik, Kassel, Germany
    Behav Sleep Med 13:375-86. 2015
    ..The design using a matched control group without sleep disorders limits the conclusions that can be drawn regarding the frequency of psychiatric diagnoses and controls with sleep problems. ..
  27. pmc Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease?
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Kassel, Germany Department of Neurology, Philipps University Marburg, Germany
    Sleep 37:431-8. 2014
    ..To analyze potential markers in sleep for early recognition of neurodegenerative disease in newly diagnosed, unmedicated patients with Parkinson disease (PD) compared to controls...
  28. ncbi The restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Germany
    Lancet Neurol 4:465-75. 2005
    ..Various other drugs, such as opioids, gabapentin, and benzodiazepines, provide alternative treatment possibilities...
  29. ncbi T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians
    Friederike von Lewinski
    Paracelsus Elena Klinik, Klinikstr 16, 34128 Kassel, Germany
    J Neurol 254:1184-8. 2007
    ..T2*-weighted magnetic resonance imaging (MRI) gradient echo (GE) sequences are sensitive for paramagnetic susceptibility changes and therefore may support the clinical differential diagnosis between MSA and PD...
  30. pmc α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
    Brit Mollenhauer
    Paracelsus Elena Klinik, Klinikstrasse 16, 34128, Kassel, Germany
    J Neural Transm (Vienna) 119:739-46. 2012
    ..We conclude from these complementary results that despite its higher levels in peripheral blood products, neurons of the brain and spinal cord represent the principal source of aSyn in human CSF...
  31. doi Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Kassel, Germany Department of Neurosurgery, University Medical Centre, Goettingen, Germany Electronic address
    Lancet Neurol 14:1161-70. 2015
    ..Pain is a common non-motor symptom of Parkinson's disease. We investigated the analgesic efficacy of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson's disease and chronic, severe pain...
  32. doi Neurochemical biomarkers in the differential diagnosis of movement disorders
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 24:1411-26. 2009
    ..In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF alpha-synuclein findings)...
  33. doi Skin complications in deep brain stimulation for Parkinson's disease: frequency, time course, and risk factors
    Friederike Sixel-Döring
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Acta Neurochir (Wien) 152:195-200. 2010
    ....
  34. doi The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases
    Friederike Sixel-Döring
    Center of Parkinsonism and Movement Disorders, Paracelsus Elena Klinik, Klinikstr 16, 34128, Kassel, Germany
    J Neurol 258:2147-54. 2011
    ..There was no evidence of a decrease in DAT binding in the majority of patients with postural and/or kinetic tremor. The striatal asymmetry index is a further helpful tool for differentiating PD from non-PD tremor syndromes...
  35. ncbi Tireless work on restless legs: guest editors' introduction
    Claudia Trenkwalder
    Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
    Mov Disord 22:S393-4. 2007
  36. doi Restless legs syndrome-current therapies and management of augmentation
    Claudia Trenkwalder
    1 Paracelsus Elena Klinik, Centre of Parkinsonism and Movement Disorders, Kassel, Klinikstrasse 16, 34128 Kassel, Germany 2 Department of Neurosurgery, University Medical Centre Göttingen, Robert Koch Strasse 40, 37075 Gottingen, Germany
    Nat Rev Neurol 11:434-45. 2015
    ....
  37. ncbi Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing
    Jan Schindehütte
    Paracelsus Elena Klinik Kassel, Klinikstrasse 16, 34128 Kassel, Germany
    Clin Neurol Neurosurg 109:188-91. 2007
    ..Two patients developed pathological laughing as a possible side-effect of ziprasidone. Ziprasidone may serve as an additional "atypical anti-psychotic" for the treatment of DP in PD but can also induce deterioration of motor function...
  38. ncbi Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
    Claudia Trenkwalder
    Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 21:1404-10. 2006
    ..The great majority of adverse events (AEs) were mild or moderate, and of expected types. Augmentation was considered an AE, but in this population of responders it did not occur...
  39. doi Substantia nigra echogenicity in progressive supranuclear palsy
    Jens Ebentheuer
    Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
    Mov Disord 25:773-7. 2010
    ..1 +/- 2.43). In RS patients a normoechogenic SN (26 of 27) and an enlarged third ventricle (mean mm) +/-SD: 10.3 +/- 2.41) was found. These differences may elucidate the pathological differences of RS and PSP-P...
  40. ncbi CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Mirko Bibl
    Department of Psychiatry, University of Goettingen, Goettingen, Germany
    Brain 129:1177-87. 2006
    ..Their distinct molecular phenotypes support the view of different pathophysiological pathways for each of these neurodegenerative diseases...
  41. ncbi Body weight in patients with Parkinson's disease
    Cornelius G Bachmann
    Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany
    Mov Disord 21:1824-30. 2006
    ..Because meal times may coincide with unpredictable off periods associated with akinesia and impaired hand-mouth coordination, PD patients also need flexible food schedules that accommodate the associated symptoms of this disease...